Market cap
₹1,230 Cr
Recently Viewed
Clear AllBSE: 539730
₹2,230.90
₹133.50
(6.37%)
As on 30-Apr-2026IST
Market cap
₹1,230 Cr
Revenue (TTM)
₹593 Cr
P/E Ratio
37.6
P/B Ratio
4.6
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹33 Cr
ROE
14 %
ROCE
16.2 %
Industry P/E
59.64
EV/EBITDA
16.8
Debt to Equity
1.2
Book Value
₹483.6
EPS
₹66.5
Face value
10
Shares outstanding
5,512,690
CFO
₹-31.33 Cr
EBITDA
₹172.77 Cr
Net Profit
₹65.13 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fredun Pharma
| 41.3 | 31.7 | 49.8 | 217.2 | 34.9 | 39.9 | 65.5 |
|
BSE Healthcare
| 2.7 | 6.8 | 7.9 | 5.7 | 24.7 | 13.8 | 11.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Fredun Pharma
| 115.0 | -14.5 | -22.4 | 32.5 | 107.1 | 84.6 | -34.3 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Fredun Pharma
|
2,230.9 | 1,229.8 | 593.5 | 32.7 | 12.8 | 21.9 | 37.6 | 4.6 |
| 2,594.1 | 21,258.3 | 1,339.4 | 356.4 | 33.2 | 23.2 | 59.7 | 12.9 | |
| 483.3 | 18,476.1 | 2,051.5 | 180.5 | 11.6 | 7.7 | 91.6 | 4.8 | |
| 699.7 | 17,327.2 | 5,365.6 | 595.0 | 16.6 | 13.3 | 29.1 | 3.4 | |
| 1,095.8 | 19,627.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.6 | 2.2 | |
| 1,738.1 | 19,938.7 | 1,419.3 | 20.1 | 8.4 | 0.5 | 991.9 | 3.4 | |
| 161.9 | 21,520.5 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.6 | |
| 970.0 | 16,018.9 | 1,284.3 | 134.4 | -- | 30.7 | 119.2 | 13.1 | |
| 467.7 | 18,887.7 | 3,738.7 | 316.7 | 12.5 | 7.5 | 59.6 | 3.9 | |
| 1,395.6 | 22,661.2 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1030.1 | 4.9 |
No Review & Analysis are available.
Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable... alkaloids; Read more
Incorporated
1987
Chairman
Daulat Medhora
Managing Director
Fredun Medhora
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Fredun Pharmaceuticals Ltd is ₹2,230.90 (BSE) as of 30-Apr-2026 IST. Fredun Pharmaceuticals Ltd has given a return of 34.9% in the last 3 years.
The P/E ratio of Fredun Pharmaceuticals Ltd is 37.63 times as on 30-Apr-2026, a 37 discount to its peers’ median range of 59.64 times.
The P/B ratio of Fredun Pharmaceuticals Ltd is 4.61 times as on 30-Apr-2026, a 35 premium to its peers’ median range of 3.41 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
15.99
|
2.23
|
|
2024
|
21.57
|
2.81
|
|
2023
|
32.60
|
4.00
|
|
2022
|
64.04
|
5.98
|
|
2021
|
91.79
|
4.29
|
The 52-week high and low of Fredun Pharmaceuticals Ltd are Rs 2,278.85 and Rs 666.00 as of 03-May-2026.
Fredun Pharmaceuticals Ltd has a market capitalisation of ₹ 1,230 Cr as on 30-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Fredun Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.